Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall-Reference-Cited by-同舟云学术

Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall

Published:2022-03-31 Issue:6 Volume:17 Page:531-546
ISSN:1746-0441
Container-title:Expert Opinion on Drug Discovery
language:en
Short-container-title:Expert Opinion on Drug Discovery

Author:

Tuccori Marco¹²^ORCID,Convertino Irma¹^ORCID,Ferraro Sara¹^ORCID,Cappello Emiliano¹^ORCID,Valdiserra Giulia¹^ORCID,de Luca Giulia¹,Franchini Massimo³⁴^ORCID,Focosi Daniele^ORCID

Affiliation:

1. Unit of Pharmacology and Pharmacovigilance - Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

2. Unit of Adverse Drug Reactions Monitoring, Pisa University Hospital, Pisa, Italy

3. Department of Transfusion Medicine and Hematology, Carlo Poma Hospital Azienda Socio Sanitaria Territoriale of Mantova, Mantova, Italy

4. Tuscany Blood Bank, Pisa University HospitalNorth-Western, Pisa, Italy

Publisher

Informa UK Limited

Subject

Drug Discovery

Link

https://www.tandfonline.com/doi/pdf/10.1080/17460441.2022.2058486

Reference76 articles.

1. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline

2. An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future

3. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

4. Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes new long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain individuals. FDA website. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-long-acting-monoclonal-antibodies-pre-exposure. Published 2021. cited 2021 Dec 31.

5. Euroepan Medicine Agency. EMA starts rolling review of evusheld (tixagevimab and cilgavimab. EMA website. cited 2021 Dec 31. Available from https://www.ema.europa.eu/en/news/ema-starts-rolling-review-evusheld-tixagevimab-cilgavimab. Published 2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option;Expert Opinion on Drug Discovery;2023-10-13

2. Adapting Neutralizing Antibodies to Viral Variants by Structure‐Guided Affinity Maturation Using Phage Display Technology;Global Challenges;2023-08-21

3. Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence;Expert Opinion on Drug Discovery;2023-01-24

4. Prescription of Anti-Spike Monoclonal Antibodies in COVID-19 Patients with Resistant SARS-CoV-2 Variants in Italy;Pathogens;2022-07-22

5. COVID-19 Treatment and Management: Two Years After the Outbreak;Trends in Medical Sciences;2022-05-23